IPAB Rejects Novartis Plea for New Tech Member (India)
This article was originally published in PharmAsia News
The Intellectual Property Appellate Board (IPAB) in India has dismissed the application by Novartis to appoint a new technical member in place of former Patent Controller S Chandrasekhar to hear the pharma firm's appeal against the Patent Office's denial of patent to its blood cancer drug Glivec. Novartis officials said Chandrasekhar had a conflict of interest due to being the Patent Controller who denied the patent rights for Glivec. A Novartis spokesperson said, "Today's decision was a summary judgment and we will not know the panel's reasoning until a full written judgment is issued. We will consider our options once we see the full text." (Click here for more
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.